ERBB2 and breast cancer: The findings of no association between use of β-blockers and BC-specific survival in patients with BC of luminal or HER2 + molecular subtypes in our cohort study are consistent with previous observational studies [16, 17, 19, 20] and was confirmed in the meta-analysis.